BiotechTube

Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hodgkin's Disease

Conditions

Hodgkin's Disease

Trial Timeline

Mar 1, 2004 → —

NCT ID
NCT00147875

About Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine

Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine is a phase 1/2 stage product being developed by Eli Lilly for Hodgkin's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00147875. Target conditions include Hodgkin's Disease.

What happened to similar drugs?

8 of 20 similar drugs in Hodgkin's Disease were approved

Approved (8) Terminated (2) Active (10)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00147875Phase 1/2Completed

Competing Products

20 competing products in Hodgkin's Disease

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
R-mabHDI and ABVD + ABVDEli LillyPhase 3
36
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
R-mabHD + ABVDEli LillyPhase 2
31
LY317615Eli LillyPhase 2
35
LY4584180 + RituximabEli LillyPhase 1
36
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
40
HRS-3738Jiangsu Hengrui MedicinePhase 1
25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
31
ABT-199 + KetoconazoleAbbViePhase 1
29
ABT-199 + RifampinAbbViePhase 1
21
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + Rituximab + BendamustineAbbViePhase 1
29